botensilimab,balstilimab
agenus
compelling phase 1b data presented by w/ botensilimab, an fc-enhanced ctla-4 inhibitor, and balstilimab (anti-pd-1) in a 3l+ crc mss pts population orr 24% dcr 74% exploratory analysis by liver involvement: all rx in pts w/o liver mx #wcgic2022 
Medical Oncology fellow at AC Camargo Cancer Center @accancercenter. Trainee and Early Career Advisory Group member volunteer @ASCO. Views are my own.